ABSTRACT
In type 2 diabetes mellitus, oral hypoglycemic agents and analogues of glucagon-like peptide-1 provide adequate glycemic control early in the disease. Insulin therapy becomes necessary for those with advanced disease. Further, some experts recommend electively starting insulin therapy in early diabetes. This review addresses practical approaches to insulin therapy, particularly when it is indicated and which regimen to use.
Footnotes
↵* The author has disclosed that he has been a reviewer for Eli Lilly and is a principal investigator in the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, funded by Sanofi-Aventis.
- Copyright © 2011 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin
- Clinical Insights Into a New, Disposable Insulin Delivery Device
- Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes